A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Must have received: concurrent chemoradiotherapy — limited-stage SCLC

Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.

Cannot have received: systemic non-specific immunomodulatory therapy (interleukin, interferon, thymosin)

Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs.

Cannot have received: Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications

Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.

Cannot have received: immune mechanism-targeted therapy

Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy.

Cannot have received: anti-angiogenic therapy

Prior treatments with anti-angiogenic therapy.